Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Tamar Securities LLC

Tamar Securities LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 35,753 shares of the biopharmaceutical company’s stock after selling 1,349 shares during the quarter. Regeneron Pharmaceuticals comprises 2.5% of Tamar Securities LLC’s portfolio, making the stock its 16th biggest holding. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $27,110,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. raised its position in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Activest Wealth Management raised its position in Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 39 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $29,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 7,439 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the sale, the director owned 1,703 shares in the company, valued at $1,652,693.38. The trade was a 81.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christine A. Poon sold 7,830 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the transaction, the director directly owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 28,228 shares of company stock worth $25,985,950 in the last ninety days. Insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. Bank of America raised their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Citigroup upped their price objective on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a “neutral” rating in a research report on Friday, October 30th. Finally, HSBC raised their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $1.45 on Friday, hitting $904.35. The company had a trading volume of 1,122,229 shares, compared to its average volume of 793,479. The stock has a market capitalization of $93.11 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 1.51 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $804.38 and a two-hundred day moving average of $742.81. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter last year, the business posted $11.83 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.